JP2014529584A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014529584A5 JP2014529584A5 JP2014524097A JP2014524097A JP2014529584A5 JP 2014529584 A5 JP2014529584 A5 JP 2014529584A5 JP 2014524097 A JP2014524097 A JP 2014524097A JP 2014524097 A JP2014524097 A JP 2014524097A JP 2014529584 A5 JP2014529584 A5 JP 2014529584A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- treatment
- administered
- pharmaceutically acceptable
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 27
- 150000003839 salts Chemical class 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 11
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 5
- 206010059594 Secondary hypogonadism Diseases 0.000 claims description 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims description 4
- 201000003368 hypogonadotropic hypogonadism Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 3
- 230000003247 decreasing effect Effects 0.000 claims description 3
- 208000000509 infertility Diseases 0.000 claims description 3
- 231100000535 infertility Toxicity 0.000 claims description 3
- 230000036512 infertility Effects 0.000 claims description 3
- 206010046766 uterine cancer Diseases 0.000 claims description 3
- 201000005670 Anovulation Diseases 0.000 claims description 2
- 206010002659 Anovulatory cycle Diseases 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- 206010064919 Hypospermia Diseases 0.000 claims description 2
- 231100000552 anovulation Toxicity 0.000 claims description 2
- 206010003883 azoospermia Diseases 0.000 claims description 2
- 230000037182 bone density Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 210000003205 muscle Anatomy 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 229960003604 testosterone Drugs 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims 3
- 230000002513 anti-ovulatory effect Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 16
- 208000001145 Metabolic Syndrome Diseases 0.000 description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 2
- 230000005906 menstruation Effects 0.000 description 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010049287 Lipodystrophy acquired Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 208000006132 lipodystrophy Diseases 0.000 description 1
- 230000011599 ovarian follicle development Effects 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- GKIRPKYJQBWNGO-QPLCGJKRSA-N zuclomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(/Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-QPLCGJKRSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161515278P | 2011-08-04 | 2011-08-04 | |
| US61/515,278 | 2011-08-04 | ||
| PCT/US2012/049451 WO2013020017A1 (en) | 2011-08-04 | 2012-08-03 | Trans-clomiphene metabolites and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018186696A Division JP2019023210A (ja) | 2011-08-04 | 2018-10-01 | トランス−クロミフェン代謝物およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014529584A JP2014529584A (ja) | 2014-11-13 |
| JP2014529584A5 true JP2014529584A5 (https=) | 2015-07-02 |
| JP6433785B2 JP6433785B2 (ja) | 2018-12-05 |
Family
ID=46724628
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014524097A Expired - Fee Related JP6433785B2 (ja) | 2011-08-04 | 2012-08-03 | トランス−クロミフェン代謝物およびその使用 |
| JP2018186696A Pending JP2019023210A (ja) | 2011-08-04 | 2018-10-01 | トランス−クロミフェン代謝物およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018186696A Pending JP2019023210A (ja) | 2011-08-04 | 2018-10-01 | トランス−クロミフェン代謝物およびその使用 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US9981906B2 (https=) |
| EP (2) | EP3351527A1 (https=) |
| JP (2) | JP6433785B2 (https=) |
| KR (1) | KR20140054110A (https=) |
| CN (1) | CN103702975B (https=) |
| AU (2) | AU2012289964B2 (https=) |
| BR (1) | BR112014000908A2 (https=) |
| CA (1) | CA2841572C (https=) |
| CL (1) | CL2014000268A1 (https=) |
| CO (1) | CO6862154A2 (https=) |
| CR (1) | CR20140124A (https=) |
| EA (1) | EA201490416A1 (https=) |
| IL (1) | IL230287B (https=) |
| MX (1) | MX355316B (https=) |
| MY (2) | MY170718A (https=) |
| NI (1) | NI201400008A (https=) |
| PH (1) | PH12014500144A1 (https=) |
| SG (1) | SG10201606425WA (https=) |
| UA (1) | UA113291C2 (https=) |
| WO (1) | WO2013020017A1 (https=) |
| ZA (1) | ZA201400406B (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120284764A1 (en) * | 2011-05-05 | 2012-11-08 | Keith Ball | Method and system for requesting services by a media device |
| UA113291C2 (xx) | 2011-08-04 | 2017-01-10 | Метаболіти транскломіфену і їх застосування | |
| CA2872644A1 (en) | 2012-05-31 | 2013-12-05 | Allergan Pharmaceuticals International Limited | Formulations and methods for vaginal delivery of antiprogestins |
| HK1216502A1 (zh) * | 2012-11-02 | 2016-11-18 | Repros Therapeutics Inc. | 用於癌症治療的反式-克羅米芬 |
| US9545411B2 (en) | 2012-11-02 | 2017-01-17 | Repros Therapeutics Inc. | Methods and compositions for treating progesterone-dependent conditions |
| WO2017123577A1 (en) * | 2016-01-12 | 2017-07-20 | Repros Therapeutics Inc. | Trans-clomiphene and progesterone receptor antagonist combination therapy for treating hormone-dependent conditions |
| RU2018133603A (ru) * | 2016-02-25 | 2020-03-25 | Эспен Парк Фармасьютикалз, Инк. | Пероральная дозированная форма двух изомеров кломифена и способ ее использования для лечения вторичного гипогонадизма и минимизации побочных эффектов лекарственного препарата у мужчин |
| EP3368506B1 (en) | 2016-04-22 | 2023-09-06 | F.I.S.- Fabbrica Italiana Sintetici S.p.A. | Process for the preparation of enclomiphene citrate having needle shaped crystal habit. |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2914563A (en) | 1957-08-06 | 1959-11-24 | Wm S Merrell Co | Therapeutic composition |
| IT951631B (it) | 1971-03-18 | 1973-07-10 | Richardson Merrell Spa | Composti utili per la separazione di isomeri ottici geometrici e strutturali e relativo procedimen to di sintesi |
| US4061733A (en) | 1976-10-15 | 1977-12-06 | Narayan Vishwanath Gunjikar | Veterinary compositions for inducing estrus in animals and method |
| US4729999A (en) | 1984-10-12 | 1988-03-08 | Bcm Technologies | Antiestrogen therapy for symptoms of estrogen deficiency |
| ATE36312T1 (de) | 1985-06-08 | 1988-08-15 | Asta Pharma Ag | Neue derivate des 1,1,2,2-tetramethyl-1,2-bis-(2fluor-4-hydroxyphenyl)-ethans. |
| US4820736A (en) * | 1987-03-20 | 1989-04-11 | Yale University | Use of clomiphene to predict fertility in a human female |
| GB8926171D0 (en) | 1989-11-20 | 1990-01-10 | Applied Research Systems | Treatment of infertility |
| JPH04312522A (ja) | 1991-04-08 | 1992-11-04 | Yoshiaki Kawashima | 徐放性錠剤の製造方法 |
| US5681585A (en) | 1991-12-24 | 1997-10-28 | Euro-Celtique, S.A. | Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| FI951193L (fi) | 1992-09-15 | 1995-03-14 | Merrell Pharma Inc | Ei-metabolisoituvat klomifeenianalogit tamoksifeeniresistenttien kasvainten hoitamiseksi |
| US5776923A (en) | 1993-01-19 | 1998-07-07 | Endorecherche, Inc. | Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone |
| GB9405304D0 (en) | 1994-03-16 | 1994-04-27 | Scherer Ltd R P | Delivery systems for hydrophobic drugs |
| EP0802787A4 (en) | 1994-06-17 | 1998-09-02 | Univ Nebraska | VECTOR FOR DELIVERY OF BIO-EFFECTIVE SUBSTANCES WITH GELLIFICATION -i (IN SITU) AND METHOD OF USE |
| DE4435368A1 (de) | 1994-09-22 | 1996-03-28 | Schering Ag | Verwendung von Aromatasehemmern zur Herstellung eines Arzneimittels zur Behandlung eines relativen Androgenmangels beim Mann |
| DE69617245T2 (de) | 1995-08-17 | 2002-07-25 | Csir, Pretoria | Produkte mit gesteuerter freisetzung |
| US5773031A (en) | 1996-02-27 | 1998-06-30 | L. Perrigo Company | Acetaminophen sustained-release formulation |
| IL120262A (en) | 1996-02-28 | 2001-01-28 | Pfizer | Droloxifene and derivatives thereof for use in increasing serum testosterone levels |
| CA2269806C (en) | 1996-10-28 | 2006-01-24 | Bernhard H. Van Lengerich | Embedding and encapsulation of controlled release particles |
| BR9809064A (pt) | 1997-04-03 | 2002-01-02 | Guilford Pharm Inc | Polìmeros biodegradáveis de poliéster de tereftalato-polifosfato, composições, artigos e métodos para fazer e usar os mesmos |
| US6653297B1 (en) | 1997-07-03 | 2003-11-25 | Medical College Of Hampton Roads | Control of selective estrogen receptor modulators |
| US6342250B1 (en) | 1997-09-25 | 2002-01-29 | Gel-Del Technologies, Inc. | Drug delivery devices comprising biodegradable protein for the controlled release of pharmacologically active agents and method of making the drug delivery devices |
| US20040176470A1 (en) | 1998-05-07 | 2004-09-09 | Steiner Mitchell S. | Method for treatment and chemoprevention of prostate cancer |
| US6413533B1 (en) | 1998-05-07 | 2002-07-02 | The University Of Tennessee Research Corporation | Method for chemoprevention of prostate cancer |
| TR200100309T2 (tr) | 1998-07-30 | 2001-05-21 | Stoller Enterprises, Inc | Bitkilerin salisilik asit ve organik aminler ile muamelesi. |
| WO2000007996A2 (en) | 1998-08-07 | 2000-02-17 | Chiron Corporation | Pyrazoles as estrogen receptor modulators |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US6583129B1 (en) | 1999-06-11 | 2003-06-24 | Watson Pharmaceuticals, Inc. | Administration of non-oral androgenic steroids to women |
| CA2321321A1 (en) | 1999-09-30 | 2001-03-30 | Isotis B.V. | Polymers loaded with bioactive agents |
| US6258802B1 (en) | 1999-10-06 | 2001-07-10 | Medical College Of Hampton Roads | Corticoid therapy |
| AU3104301A (en) | 2000-01-20 | 2001-07-31 | Noven Pharmaceuticals, Inc. | Compositions and methods to effect the release profile in the transdermal administration of active agents |
| BR0108107A (pt) | 2000-01-28 | 2003-03-11 | Endorech Inc | Moduladores seletivos dos receptores de estrogênio em combinação com estrogênios; kits e composições farmacêuticas para praticar tal combinação; bem como a administração da referida combinação |
| WO2001091744A1 (en) | 2000-05-26 | 2001-12-06 | Harry Fisch | Methods of treating androgen deficiency in men using selective antiestrogens |
| US7067557B2 (en) | 2000-05-26 | 2006-06-27 | Harry Fisch | Methods of treating androgen deficiency in men using selective antiestrogens |
| JP2004507465A (ja) | 2000-08-11 | 2004-03-11 | ワイス | エストロゲン受容体陽性癌腫の治療方法 |
| US6503894B1 (en) | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
| US20040192598A1 (en) | 2000-10-11 | 2004-09-30 | Laura Kragie | Composition and method of alleviating adverse side effects and/or enhancing efficacy of agents that inhibit aromatase |
| WO2002055020A2 (en) | 2000-12-11 | 2002-07-18 | Testocreme Llc | Topical testosterone formulations and associated methods |
| US7173064B2 (en) | 2001-07-09 | 2007-02-06 | Repros Therapeutics Inc. | Methods and compositions with trans-clomiphene for treating wasting and lipodystrophy |
| AU2002318225B2 (en) | 2001-07-09 | 2007-12-13 | Repros Therapeutics Inc. | Methods and materials for the treatment of testosterone deficiency in men |
| US6645974B2 (en) | 2001-07-31 | 2003-11-11 | Merck & Co., Inc. | Androgen receptor modulators and methods for use thereof |
| EP1429779A2 (en) | 2001-09-21 | 2004-06-23 | Merck & Co., Inc. | Androstanes as androgen receptor modulators |
| US20060269611A1 (en) | 2001-11-29 | 2006-11-30 | Steiner Mitchell S | Prevention and treatment of androgen-deprivation induced osteoporosis |
| US7105679B2 (en) | 2001-12-19 | 2006-09-12 | Kanojia Ramesh M | Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators |
| US7135575B2 (en) | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| US20050042268A1 (en) | 2003-07-16 | 2005-02-24 | Chaim Aschkenasy | Pharmaceutical composition and method for transdermal drug delivery |
| US20080242726A1 (en) | 2004-07-14 | 2008-10-02 | Podolski Joseph S | Trans-Clomiphene for the Treatment of Benign Prostate Hypertrophy, Porstate Cancer, Hypogonadism Elevated Triglycerides and High Cholesterol |
| US20060293294A1 (en) | 2004-09-03 | 2006-12-28 | Hormos Medical Corporation | Method for treatment or prevention of androgen deficiency |
| CN101115709B (zh) * | 2004-12-13 | 2011-04-13 | 小野药品工业株式会社 | 氨基羧酸衍生物及其医药用途 |
| NZ556499A (en) * | 2005-02-04 | 2011-02-25 | Repros Therapeutics Inc | Methods and materials with trans-clomiphene for the treatment of male infertility |
| EP1853298A2 (en) | 2005-02-11 | 2007-11-14 | Regeneron Pharmaceuticals, Inc. | Therapeutic combination of a vegf antagonist (vegf trap) and an anti-hypertensive agent |
| BRPI0609389A2 (pt) * | 2005-03-22 | 2010-03-30 | Repros Therapeutics Inc | tablete, composição e respectivos usos |
| JP2008543855A (ja) | 2005-06-13 | 2008-12-04 | ライジェル ファーマシューティカルズ， インコーポレイテッド | 変形性骨疾患を処置するための方法および組成物 |
| CA2617905A1 (en) | 2005-08-05 | 2007-02-15 | Repros Therapeutics Inc. | Methods and compositions for treating female infertility using clomiphene |
| US7613937B2 (en) | 2005-10-31 | 2009-11-03 | Hewlett-Packard Development Company, L.P. | Method and apparatus for utilizing a microcontroller to provide an automatic order and timing power and reset sequencer |
| EP1991241A4 (en) | 2006-02-23 | 2009-07-08 | Iomedix Sleep Internat Srl | COMPOSITIONS AND METHODS FOR INTRODUCING AND MAINTAINING HIGH-QUALITY SLEEPING |
| EP1829534A1 (en) | 2006-03-02 | 2007-09-05 | Laboratorios Del Dr. Esteve, S.A. | Use of compounds binding to the sigma receptor for the treatment of metabolic syndrome |
| WO2008005469A2 (en) | 2006-06-30 | 2008-01-10 | Schering Corporation | Igfbp2 biomarker |
| ES2381175T3 (es) | 2007-06-26 | 2012-05-23 | Media Patents, S. L. | Dispositivo para gestionar grupos multidifusión |
| US8106037B2 (en) | 2007-08-03 | 2012-01-31 | The Brigham And Women's Hospital, Inc. | Identification and treatment of estrogen responsive prostate tumors |
| BRPI0818637A2 (pt) | 2007-10-16 | 2015-04-07 | Repros Therapeutics Inc | Métodos de tratamento de sintoma da síndrome metabólica, de glicose em jejum prejudicada, da síndrome metabólica e de redução de níveis de glicose em, jejum em sujeito com hipogonadismo hipogonadotrófico secundário ou idiopático |
| US20100111901A1 (en) | 2008-11-03 | 2010-05-06 | Auspex Pharmaceuticals, Inc. | Triazole inhibitors of aromatase |
| TW201500041A (zh) | 2008-11-07 | 2015-01-01 | Repros Therapeutics Inc | 用於代謝症候群與第２型糖尿病的反式氯米芬 |
| US20100144687A1 (en) | 2008-12-05 | 2010-06-10 | Glaser Rebecca L | Pharmaceutical compositions containing testosterone and an aromatase inhibitor |
| UA113291C2 (xx) | 2011-08-04 | 2017-01-10 | Метаболіти транскломіфену і їх застосування | |
| WO2013020215A1 (en) | 2011-08-09 | 2013-02-14 | Adams Kenneth W | Use of aromatase inhibitor or estrogen blocker for increasing spermatogenesis or testosterone levels in males |
| JP2015508825A (ja) | 2012-02-29 | 2015-03-23 | レプロス セラピューティクス インコーポレイティド | アンドロゲン欠乏症を治療するための併用療法 |
| KR20150041793A (ko) | 2012-08-21 | 2015-04-17 | 레프로스 쎄라피우틱스 아이엔씨. | 트랜스-클로미펜 제형 및 그의 용도 |
| CN103351304B (zh) | 2013-07-01 | 2015-12-09 | 暨明医药科技（苏州）有限公司 | 一种克罗米芬的合成方法 |
-
2012
- 2012-03-08 UA UAA201402168A patent/UA113291C2/uk unknown
- 2012-08-03 US US14/236,868 patent/US9981906B2/en not_active Expired - Fee Related
- 2012-08-03 CN CN201280038230.6A patent/CN103702975B/zh not_active Expired - Fee Related
- 2012-08-03 MY MYPI2014000022A patent/MY170718A/en unknown
- 2012-08-03 AU AU2012289964A patent/AU2012289964B2/en not_active Ceased
- 2012-08-03 CA CA2841572A patent/CA2841572C/en not_active Expired - Fee Related
- 2012-08-03 EP EP18161551.9A patent/EP3351527A1/en not_active Withdrawn
- 2012-08-03 JP JP2014524097A patent/JP6433785B2/ja not_active Expired - Fee Related
- 2012-08-03 MX MX2014000825A patent/MX355316B/es active IP Right Grant
- 2012-08-03 WO PCT/US2012/049451 patent/WO2013020017A1/en not_active Ceased
- 2012-08-03 KR KR1020147004588A patent/KR20140054110A/ko not_active Ceased
- 2012-08-03 MY MYPI2017001676A patent/MY191802A/en unknown
- 2012-08-03 PH PH1/2014/500144A patent/PH12014500144A1/en unknown
- 2012-08-03 BR BR112014000908A patent/BR112014000908A2/pt active Search and Examination
- 2012-08-03 EA EA201490416A patent/EA201490416A1/ru unknown
- 2012-08-03 SG SG10201606425WA patent/SG10201606425WA/en unknown
- 2012-08-03 EP EP12750508.9A patent/EP2744777A1/en not_active Withdrawn
-
2014
- 2014-01-02 IL IL230287A patent/IL230287B/en active IP Right Grant
- 2014-01-17 ZA ZA2014/00406A patent/ZA201400406B/en unknown
- 2014-01-24 CO CO14014339A patent/CO6862154A2/es unknown
- 2014-01-30 NI NI201400008A patent/NI201400008A/es unknown
- 2014-02-03 CL CL2014000268A patent/CL2014000268A1/es unknown
- 2014-03-13 CR CR20140124A patent/CR20140124A/es unknown
-
2017
- 2017-06-20 AU AU2017204171A patent/AU2017204171A1/en not_active Abandoned
-
2018
- 2018-10-01 JP JP2018186696A patent/JP2019023210A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014529584A5 (https=) | ||
| JP2013501731A5 (https=) | ||
| RU2017117413A (ru) | Пролекарства карбидопа и l-dopa и их применение для лечения болезни паркинсона | |
| TW200410711A (en) | Prevention and treatment of androgen-deprivation induced osteoporosis | |
| RU2012148710A (ru) | Органическое соединение для применения при лечении рака печени | |
| MXPA05007857A (es) | Moduladores derivados de indol de receptores nucleares de hormonas esteroideas. | |
| JP2014511383A5 (https=) | ||
| FI3518932T3 (fi) | Eturauhassyövän hoito | |
| RU2014113334A (ru) | Применение ингибитора ароматазы для лечения гипогонадизма и родственных заболеваний | |
| JP2017533972A5 (https=) | ||
| JP2022500366A (ja) | 肝疾患治療のための併用療法 | |
| JP2014512355A5 (https=) | ||
| RU2012108656A (ru) | Применение 4-аминопиридина для улучшения состояния при нейрокогнитивном и/или нейропсихиатрическом нарушении у пациентов с демиелинизирующими и другими заболеваниями нервной системы | |
| CN107072969B (zh) | 使用顺式氯米芬治疗雄激素剥夺疗法诱导的热潮红和骨丢失 | |
| JP2012525358A5 (https=) | ||
| KR20160067225A (ko) | 암 환자에서 근육 소모를 치료하는 선택적 안드로겐 수용체 조절물질 및 화학치료제 | |
| RU2017134553A (ru) | Хорошо растворимые в воде соли фенилалкиламина - быстродействующего блокатора кальциевых каналов, и их применение | |
| JP2015506988A5 (https=) | ||
| JP2015533150A (ja) | 前立腺がんの根治的又は対症的処置における使用のためのホスフェストロール | |
| WO1995012383A1 (en) | An injectable solution of testosterone undecanoate | |
| JP2015506988A (ja) | 半減期の短い選択的エストロゲン受容体モジュレーターおよびその使用 | |
| RU2014111060A (ru) | Лиганды рецептора эстрогена и способы их применения | |
| JP2014524479A5 (https=) | ||
| JP2013503908A5 (https=) | ||
| JP2016509571A (ja) | 雌哺乳動物でのがんの根治的又は対症的処置における使用のためのホスフェストロール |